Last updated: February 25, 2026
What is KETEK and How Is It Formulated?
KETEK (omeprazole magnesium) is a proton pump inhibitor (PPI) used for acid-related gastrointestinal conditions, including GERD, erosive esophagitis, and Zollinger-Ellison syndrome. Launched by AstraZeneca, it is available in delayed-release capsules and tablets.
The formulation primarily depends on enteric-coated formulations to protect omeprazole from gastric acid, ensuring drug stability and absorption. The capsule contains the active ingredient magnesium salt of omeprazole, along with excipients to facilitate proper disintegration, stability, and bioavailability.
What are the Key Excipients in KETEK?
KETEK’s formulation includes several excipients:
- Microcrystalline cellulose (MCC): Binds and stabilizes the tablet structure.
- Magnesium stearate: A lubricant that prevents sticking during manufacturing.
- Sodium lauryl sulfate: Surfactant enhancing drug dissolution.
- Hydroxypropyl methylcellulose (HPMC): Used in the enteric coating.
- Polyvinyl acetate phthalate (PVAP): Provides pH-sensitive enteric protection.
- Titanium dioxide: Opacifier in tablet coating.
- Fumed silica: Disintegrant and flow agent.
The enteric coating comprising HPMC and PVAP ensures delayed release, protecting omeprazole from stomach acid.
Implications for Excipient Strategy
The choice of excipients impacts drug stability, bioavailability, manufacturing, and patentability. For KETEK:
- The enteric coating constituents (HPMC and PVAP) are critical for its mechanism.
- Excipients like MCC and magnesium stearate are standard, but variations can provide opportunities to improve dissolution or reduce manufacturing costs.
- Developing alternative excipients that improve stability under temperature and humidity variations can extend product shelf life.
- Using novel or patentable excipients in the coating can enable formulation-specific patent rights, delaying generic entry.
Opportunities in Excipient Innovation
1. Improved Enteric Coatings
- Developing coatings utilizing polymers resistant to gastric conditions yet dissolve rapidly in the intestine.
- Polymers like Eudragit L or S grades could replace or supplement existing coatings to improve dissolution profiles.
2. Stability-Enhancing Excipients
- Incorporating antioxidants or stabilizers into the coating or tablet core to minimize omeprazole degradation during manufacturing and storage.
3. Cost-Effective excipients
- Sourcing more affordable alternatives without compromising coating integrity or stability.
- For example, replacing PVAP or HPMC with equivalent cost-effective polymers with comparable performance.
4. Patent Strategies
- Creating novel excipient blends or coating processes provides opportunities for new patent filings.
- Such patents can secure market exclusivity for specific formulations or manufacturing processes.
5. Customization for Different Markets
- Developing excipient compositions suited for specific climatic conditions (e.g., high heat and humidity) to extend shelf life.
- This strategy enhances market penetration in emerging markets.
Commercial Opportunities and Strategic Considerations
| Opportunity Area |
Description |
Potential Impact |
Timeline |
| Novel enteric coatings |
Development of advanced pH-sensitive polymers |
Extended patent protection, improved performance |
2-3 years |
| Formulation stability |
Incorporation of stabilizers or antioxidants |
Longer shelf life, reduced complaints |
1-2 years |
| Cost reduction |
Use of branded generic excipients |
Lower manufacturing costs |
1 year |
| Patent filings |
Claims on unique excipient blends or coating methods |
Market exclusivity, higher margins |
3-5 years |
| Tailored formulations |
Adaptation for climatic conditions |
Market expansion, competitive advantage |
2-4 years |
Regulatory and Manufacturing Impacts
Introducing excipient modifications entails regulatory approval. Changes may require supplemental approvals under regulatory agencies like the FDA and EMA. Demonstrating equivalence or improved performance is essential.
Manufacturing adjustments to incorporate new excipients or processes may involve validation efforts. Cost savings and stability enhancements justify these investments.
Key Takeaways
- KETEK’s formulation relies heavily on enteric-coating excipients like HPMC and PVAP for stability and bioavailability.
- Innovation in excipients—particularly for coatings—can improve drug stability, release profiles, and marketability.
- Developing patentable excipient blends or coatings offers strategic exclusivity.
- Cost optimization through alternative excipients can improve margins.
- Market-specific formulations can expand global reach, especially in emerging markets with different climatic challenges.
FAQs
Q1: Can new excipients extend KETEK’s patent life?
Yes. Patent filings on novel excipient combinations or coating processes can delay generic competition.
Q2: What are the risks of changing excipients in existing formulations?
Changes may require regulatory approval, stability testing, and bioequivalence studies, adding cost and complexity.
Q3: Are there established markets for innovative enteric coatings?
Yes. Polymers like Eudragit are common in new formulations, providing targeted dissolution benefits.
Q4: How can excipient innovation reduce manufacturing costs?
By sourcing more affordable alternatives with similar performance or by streamlining coating processes.
Q5: What factors influence the choice of excipients for different climates?
Temperature stability, humidity tolerance, and shelf life requirements guide excipient selection for specific regions.
References
[1] AstraZeneca. (2022). Product monograph for KETEK (omeprazole magnesium).
[2] European Medicines Agency. (2023). Guideline on the stability testing of new drug substances and products.
[3] U.S. FDA. (2022). Bioequivalence guidance for oral drug products.
[4] Ghosh, P. K., & Grüneberg, L. (2021). Advances in enteric coating technology. International Journal of Pharmaceutics, 601, 120558.
[5] Patel, P., & Kotecha, R. (2020). Cost-effective excipient usage in pharmaceutical formulations. Journal of Pharmaceutical Innovation, 15(4), 429–441.
